Brokerage Firm Rating on C.R. Bard (BCR)

C.R. Bard (BCR) : 1 brokerage houses believe that C.R. Bard (BCR) is a Strong Buy at current levels. 1 Analyst considers the fundamentals to be worthy of a Buy recommendation. 13 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on C.R. Bard (BCR). Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 15 Wall Street Analysts endorse the stock as a Hold with a rating of 2.8.

C.R. Bard (BCR) : The most positive equity analysts on C.R. Bard (BCR) expects the shares to touch $264, whereas, the least positive believes that the stock will trade at $220 in the short term. The company is covered by 10 Wall Street Brokerage Firms. The average price target for shares are $239.4 with an expected fluctuation of $12.83 from the mean.


Company shares have received an average consensus rating of Hold for the current week C.R. Bard (NYSE:BCR): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $222.91 and $222.04 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $223.49. The buying momentum continued till the end and the stock did not give up its gains. It closed at $223.11, notching a gain of 0.22% for the day. The total traded volume was 427,085 . The stock had closed at $222.61 on the previous day.

In a related news, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the officer (Senior Vice President and CFO) of Bard C R Inc /Nj/, Holland Christopher S had sold 3,970 shares worth of $872,924 in a transaction dated May 27, 2016. In this transaction, 3,970 shares were sold at $219.88 per share.

C. R. Bard, Inc. (Bard) and its subsidiaries are engaged in the design, manufacture, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. . The Company reports its sales in four major product group categories: vascular, urology, oncology and surgical specialty. The Company also has a product group of other products. The Companys vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and heart arrhythmias. Its urology products include basic urology drainage products, fecal and urinary continence products, urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and other soft tissue repairs, in addition to hemostats and surgical sealants.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.